SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS - VIVUS - New VVUS Thread

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stuart Scolnik who wrote (29)12/10/1997 12:51:00 PM
From: Linda Kaplan  Read Replies (1) of 50
 
Headline: Genesis Downgrades Vivus to Long-Term Buy; Analyst Cuts 1997
Revenue/Earnings Estimates

======================================================================
SAN FRANCISCO, Dec. 10 /PRNewswire/ -- Genesis Merchant Group
Securities analyst D. Curtis Hogue downgraded his rating on Vivus, Inc.
(Nasdaq-NNM: VVUS) to long-term buy from strong buy based on the uncertainty
surrounding the company's ability to manage the transition from one production
facility to two facilities.
Hogue noted, "Our 1998 EPS estimates and price target are currently under
review, but we anticipate having to lower these numbers significantly. Based
on our initial analysis, we estimate an EPS range of $1.30 to $1.50 for 1998."
Hogue is lowering his full year and Q4 estimates for 1997 as well. Product
revenue estimates for Q4 1997 are dropping to $28.6 million from $39.5 million
and Q4 EPS estimates are being lowered to $0.18 per share from $0.34. "This
effectively lowers our 1997 EPS estimate from $1.21 to $1.04 per share," he
added.

SOURCE Genesis Merchant Group Securities
-0- 12/10/97
/CONTACT: D. Curtis Hogue of Genesis Merchant Group Securities,
415-677-1500/
/Web site: sternco.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext